The murine monoclonal antibody mAb-1H1l raised against malondialdehyde (MDA)-modified LDL, was used to detect cross-reacting material in human atheromatous tissue and in plasma. MDA-modified LDL levels in plasma were 0.19±0.02 mg/dl (mean±SEM) in 44 control subjects, 0.24±0.02 mg/dl in 15 patients with chronic stable angina pectoris (P = NS vs LDL cholesterol matched controls), 1.4±0.1 mg/dl in 60 patients with acute myocardial infarction (P < 0.001 vs controls), and 0.86±0.11 mg/dl in 22 patients with carotid atherosclerosis (P < 0.001 vs controls). Modified LDL, isolated from pooled LDL of 10 patients, showed a higher electrophoretic mobility on agarose gels, a higher content of thiobarbituric acid reactive substances, and a higher cholesterol/protein ratio than native LDL and had a similar reactivity (antigen/protein ratio) in the assay as the in vitro MDA-modified LDL used for calibration. Its apo B-100 moiety was not fragmented. Uptake of this modified LDL by macrophages resulted in foam cell generation. In conclusion, elevated plasma levels of atherogenic MDAmodified LDL may be a marker for unstable atherosclerotic cardiovascular disease. (J. CliH. Invest. 1995.95:2611-2619 
Introduction
Subendothelial accumulation of foam cells, primarily derived from monocytes/macrophages by uptake of LDL, plays a key role in the initiation of atherosclerosis (reviewed in reference 1). The LDL receptor (2) , which is down-regulated when the intracellular cholesterol levels are increased, is not involved in intracellular cholesterol accumulation in foam cells. However, macrophages avidly accumulate oxidized LDL, by uptake via scavenger receptors that are unresponsive to intracellular cholesterol levels (2, 3) . Oxidative modification of LDL may be obtained in vitro by incubation with cultured cells (4) , with purified lipoxygenase in the presence of phospholipase A2 (5), or with Cu2+ (6) . In vitro oxidation occurs in three phases; a lag, a propagation, and a decomposition phase. During the lag phase, endogenous LDL antioxidants (e.g., vitamin E) are consumed. During the propagation phase, unsaturated fatty acids are rapidly oxidized to lipid hydroperoxides, which are converted during the decomposition phase to a variety of other products including reactive aldehydes (e.g., malondialdehyde
[MDA]') (7) . These aldehydes may react with lysine residues in the LDL apo B-100 moiety, resulting in a decreased affinity of apo B-100 for the LDL receptor and an increased affinity for scavenger receptors. Oxidatively modified LDL has previously been demonstrated in atherosclerotic lesions, but not in normal arteries (8) (9) (10) , whereas LDL eluted from atherosclerotic lesions, but not from normal arteries, is rapidly taken up by macrophages (1 1, 12) . Furthermore, autoantibodies against oxidized LDL have been demonstrated in plasma (13, 14) and in atherosclerotic lesions (15) . However, direct evidence for the occurrence of oxidized LDL in circulating blood is lacking.
In the present study, we produced and characterized a murine monoclonal antibody (mAb-lHI 1) cross-reacting with MDA-modified apo B-100, but not with native apo B-100, that allowed the detection of modified LDL in atheromatous lesions and in plasma of patients with atherosclerotic disease. Modified LDL isolated from plasma had a reactivity in the immunoassay similar to that of in vitro MDA-modified LDL used for production of the antibody and calibration of the assay.
Methods
Lipoproteins: preparation and modification. LDL were isolated from pooled sera of fasting normolipidemic donors by density gradient ultracentrifugation in a tabletop ultracentrifuge (TL-100, Beckman Instruments, Inc., Fullerton, CA) for 2 h (16) , and were dialyzed at 4°C against 0.15 M NaCl containing 0.01% EDTA (pH 7.5). The lipoproteins were used within 2 wk after isolation. All lipoprotein preparations were sterilized by filtration, using a 0.45-pM low-protein binding filter (Millex; Millipore Corp., Brussels, Belgium) and stored at 4°C under nitrogen in the presence of 20 pM vitamin E and 10 !M butylated hydroxytoluene to prevent in vitro oxidation, and of 10 IU/ml aprotinin to prevent protein degradation. MDA-modified albumin, MDA-modified polylysine, MDA-modified LDL, and copper-oxidized LDL were prepared as described elsewhere (17) (18) (19) . Delipidation of LDL was performed as previously described (20 vol/vol), dried in a forced air oven at 50C followed by development in chloroform/methanol/formic acid (65:25:10, vol/vol) in the second dimension (22) . Lipids were transiently visualized by iodine and their identity was confirmed by specific staining (amino and phosphate groups) and comparison of Rf values with those of standards. Identified spots were scraped into Pyrex tubes (Corning Inc., Corning, NY) and their phosphate content was determined after wet ashing (23) . Plasma proteins were separated by gel-exclusion chromatography on a Superose 6HR 10/30 column (24) in a fast protein liquid chromatography system (Pharmacia Diagnostics AB, Uppsala, Sweden). Modified LDL was purified from the isolated LDL fractions of patients with acute myocardial infarction by ion-exchange chromatography on a mono Q-Sepharose column in the fast liquid chromatography system (25, 26) . Alternatively, modified LDL was purified from the isolated LDL fractions of patients with acute myocardial infarction by affinity chromatography on immobilized mAb-IHIl1 (27) .
Characterization ofthe monoclonal antibody mAb-JHIl. (14) . Immobilized antigens for this assay included native LDL prepared from pooled plasma (protected against in vitro oxidation as described above), MDA-modified LDL (prepared as described above starting from the same native LDL preparation) and HSA. The plasma samples were diluted 100-fold, and incubated for 2 h at room temperature in the microtiter plates. The wells were then washed and incubated for 1 h with horseradish peroxidase-conjugated goat IgG raised against human immunoglobulins and washed again. The peroxidase reaction was then performed by addition of 100 /Ag/ml o-phenylenediamine and 0.003% hydrogen peroxide. After of the other lipoproteins with phosphotungstic acid and magnesium. The LDL cholesterol levels in plasma samples with triglyceride levels < 400 mg/dl, were calculated using the Friedewald formula. The apo B-100 levels were measured as described previously (29) . Protein concentrations were measured according to Lowry (30) .
Cellular uptake ofmodified LDL Murine J774 macrophages (American Type Culture Collection, Rockville, MD) were seeded in 35-mm dishes at a cell density of 2 x 106 cells/dish, grown for 24 h in 2 ml DMEM containing 10% FCS in a 10% CO2 atmosphere and used as confluent monolayers. The cells were incubated for 24 h in serum-free DMEM containing 10 mg HSA/ml, and with native or modified LDL for 24 h in serum-free medium containing 10 mg HSA/ml. The plates were washed with PBS, fixed for 1 h with 4% formaldehyde in PBS, and then briefly immersed in 60% isopropanol. Cells were stained with 1% oil red 0 in 60% isopropanol for 1 h at 40C, rinsed in PBS, and mounted for light microscopic evaluaton. Foam cells were identified as previously described (31) .
Statistical analysis. The statistical significance of differences in plasma levels of MDA-modified apo B-100 levels between control subjects and patients was determined using the Mann-Whitney U test. The correlation between MDA-modified apo B-100 and cholesterol levels, age, or autoimmune antibody titers was determined with Pearsons' test.
Results
Characterization of monoclonal antibodies mAb-JHJJ and mAb-13F6. The apo B-100 molecules of in vitro MDA-modified LDL used for calibration of the assay were found to contain on average 244 modified lysines (out of a total of 356). Modification of lysines resulted in a threefold increased electrophoretic mobility in 1% agarose gels (Fig. 1) . SDS-PAGE revealed that its apo B-100 moiety was intact (not shown). MDA-modified LDL had a decreased affinity for the LDL receptor and an increased affinity for the scavenger receptor, as evidenced by its enhanced uptake by macrophages in vitro (10). The apo B-100 molecules of copper-oxidized LDL were found to contain an average 210 modified lysines, resulting in a 2.5-fold increased electrophoretic mobility (Fig. 1) . Furthermore, its apo B-100 moiely was highly fragmented (not shown).
The association constant for the binding of mAb-IHI to immobilized MDA-modified LDL was 109 M-', whereas its association constant for native LDL was < IO' M-1. The maximal number of binding sites per apo B-100 molecule was -2 (20 101 "bound antibody molecules per 12 X 1011 immobilized apo B-100 molecules). The specificity of mAb-iHi 1 was further derived from the inhibition of its binding to immobilized MDAmodified LDL in the presence of increasing concentrations of different soluble ligands (Fig. 2 A) . 50% inhibition was obtained with 1 nM MDA-modified LDL, 50 nM copper-oxidized LDL, and 500 nM native LDL, respectively. Delipidation of LDL and reconstitution of the lipid environment of LDL yielded soluble apo B-100 detergent complexes, MDA-modification of which yielded immunoreactive material with the same affinity for mAb-IHI 1 as MDA-modified LDL (Fig. 2 A) . 20-fold higher molar concentrations of MDA-modified albumin were required to obtain 50% inhibition. Up to 1 MM MDA-modified lysine did not affect mAb-IHI binding (not shown). The specificity of mAb-1Hl 1 for MDA-modified LDL was further confirmed by Western blot analysis (Fig. 1) .
In contrast, Fig. 2 B illustrates that soluble MDA-modified LDL, copper-oxidized LDL, and native LDL, inhibited the binding of mAb-13F6 to immobilized MDA-modified LDL to the same extent. Cross-reactivity of mAb-13F6 with all ligands was further confirmed by Western blot analysis (Fig. 1) .
Immunodetection of MDA-modified LDL in carotid atherosclerotic lesions. Endarterectomy specimens from patients with established carotid atherosclerosis displayed typical atheromatous plaques with necrotic cores containing lipid particles, cell debris, and interspersed calcium deposits. Microscopic evaluation of three representative lesions (Fig. 3) revealed lipid-like material staining with oil red 0 (not shown), which could be immunostained with mAb-lHlI (Fig. 3, A-C ), but not with the irrelevant antibody mAb-17C8 (not shown). Staining with mAb-IHI was inhibited with MDA-modified LDL but not with native LDL (not shown). Immunoreactive material was associated with smooth muscle cells (Fig. 3 D) and with macrophages (Fig. 3 E) as evidenced by specific staining of these cells.
(not shown). MDA-modified LDL could also be demonstrated in the necrotic lipid core (Fig. 3 F) .
Quantitation ofMDA-modified apo B-100 in plasma. MDAmodified apo B-100 in plasma was quantitated using an immunoassay based on inhibition of the binding of mAb-IHi 1 to the wells of microtiter plates coated with MDA-modified LDL. The lower limit of detection was 0.05 mg/dl of MDA-modified LDL 0.22±0.02 and 0.18±0.02 mg/dl, respectively (Table I) .
MDA-modified LDL levels in 15 patients with chronic stable angina pectoris were 0.24±0.02 mg/dl and thus were not different from those in controls matched for LDL cholesterol (Table I) . Plasma MDA-modified LDL levels in samples obtained from 60 patients early after the onset of acute myocardial infarction were 1.4±0.1 mg/dl (P-< 0.001 vs controls matched for LDL cholesterol). The patient population was retrospectively subdivided in two groups based on age: group I with patients younger than 60 yr (55+1 yr, n = 24) and group II with patients older than 60 yr (72±2 yr, n = 36). The plasma LDL cholesterol levels and apo B-100 levels in the two groups were very similar and were also not different from those in the older control group (Table I) . The HDL levels were, however, lower in the patients. MDA-modified LDL levels were significantly increased in patients matched for both age and LDL cholesterol (group I in Table I ). The MDA-modified LDL levels were not different in the two groups of patients (Table I) .
In 56 out of 60 plasma samples from patients with acute myocardial infarction the level was 20.5 mg/dl (mean value + 2 SD in control subjects and patients with chronic stable angina pectoris). These samples were considered to be positive. The frequency of positive samples in the patients was thus > 90%.
A set of 10 plasma samples of patients were thawed, assayed, and frozen again. The MDA-modified LDL levels in these samples were 1.4±0.1 mg/dl after the first thawing, 1.3±0.2 mg/dl after the second thawing, and 1.5±0.2 mg/dl after the third thawing.
Plasma MDA-modified LDL levels in 22 patients with carotid atherosclerosis were 0.86±0.11 mg/dl (P < 0.001 vs matched controls) ( Table I) . MDA-modified LDL levels again did not correlate with LDL cholesterol, total apo B-100, and HDL cholesterol levels or with age. The MDA-modified apo B-100 levels were significantly higher in patients with subacutely occluded carotid arteries (1.3±0.18 mg/dl) than in patients with similar carotid stenosis but without carotid artery occlusion (0.48±0.03 mg/dl; P < 0.001) ( Table II) . The frequency of positive samples was 30% for patients with extensive stenosis without subacute carotid artery occlusion and 90% for patients with similar stenosis, but complicated with subacute carotid artery occlusion.
Measurement of IgG autoantibody titers. The IgG autoantibody titers against MDA-modified LDL were 6.8±0.7 (mean±SEM) in controls, 8.6±1.0 in patients with chronic stable angina pectoris, 7.8±1.2 in patients with carotid atherosclerosis, and 7.5±0.3 in patients with acute myocardial infarction (all P = NS vs controls). The IgG antibody titers against MDAmodified LDL in plasma samples of carotid atherosclerosis patients with MDA-modified LDL levels > 0.5 mg/dl were 6.8±0.7 (n = 12) as compared to 8.8±1.6 (n = 10) in plasma samples of carotid atherosclerosis patients with MDA-modified LDL levels < 0.5 mg/dl (P = NS). Corresponding values were 6.6±0.4 (n = 54) for acute myocardial infarction patients with significantly elevated levels of MDA-modified LDL as compared to 8.4±0.4 (n = 6) for acute myocardial infarction patients with lower levels of MDA-modified LDL (P = NS).
Characterization of immunoreactive material. Six samples obtained from acute myocardial infarction patients with MDAmodified apo B-100 levels > 1 mg/dl were applied to a Superose 6HR 10/30 column. 77±4% (mean±SEM, n = 6) of the immunoreactive material was recovered in the LDL fractions. The elution profile of a representative sample is illustrated in Fig. 4 . No immunoreactive material migrated in the serum albumin position. When in vitro MDA-modified LDL was added to a final concentration of 2 mg/dl in two plasma samples obtained from control subjects with MDA-modified LDL < 0.1 mg/dl, 80% of the immunoreactive material was recovered in the LDL fractions separated by gel-exclusion chromatography (data not shown). Agarose gel electrophoresis revealed that only the plasma of patients contained a LDL fraction with increased electrophoretic mobility (Fig. 5) . Therefore, two pools of LDL of 10 patients each were applied to a mono Q-Sepharose ionexchange column. The LDL was separated in two fractions: one that migrated in the position of native LDL (peak I in Fig. 6 and lane 5 in Fig. 5 ) and one that migrated in the position of in vitro MDA-modified LDL (peak II in Fig. 6 and lane 6 in Fig. 5 ). 74% of the immunoreactive material applied to the The data represent means±SEM. CA, carotid atherosclerosis. Fraction Number Figure 4 . Gel filtration on a Superose HR 10/30 column of a citrated plasma sample obtained from a patient with acute myocardial infarction.
The sample contained 880 ,.sg MDA-modified LDL and its protein pattern was representative for six samples that were analyzed. 200 ml plasma was applied to the column equilibrated with 0.1 M citrate buffer, pH 7.4, containing 0.01% EDTA) and 10 IU/ml aprotinin; 0.5-ml fractions were collected. Absorbance at 280 nm (.) and MDA-modified LDL levels (micrograms/mililiter) (A), measured in the mAb-lHl based ELISA, are plotted vs the fraction number. The gel filtration column was calibrated with VLDL (peak atfraction 17), LDL (peak at fraction 23), HDL (peak atfraction 32), IgG (peak at fraction 33), and serum albumin (peak at fraction 35).
column was recovered in peak II (Fig. 6 ). The relative electrophoretic mobility (Fig. 5 ) of this fraction, its extent of lysine modification, and its reactivity in the mAb-1Hl 1 based ELISA (Table EII) was very similar to that of in vitro MDA-modified LDL. The apo B-100 moiety of the MDA-modified LDL isolated from the plasma was not fragmented (Fig. 6 B) , its cholesterol/protein and phospholipid/protein ratios were somewhat higher than those of native LDL (Table III) ; its ratio of cholesterol to cholesterol esters and its level of unsaturated fatty acids were not different from that of native LDL and lysophosphatidylcholine was not detected (Table III) . The characteristics of the LDL fraction that was isolated from pooled LDL of patients by affinity chromatography on immobilized mAb-iHI 1 were very similar to those of the fraction peak II that was isolated by ion-exchange chromatography, whereas the characteristics of the peak I fraction were very similar to those of LDL isolated from pooled LDL of control subjects by affinity chromatography on immobilized mAb-13F6. Foam cell generation in J774 macrophages. Fig. 7 represents light micrographs of J774 macrophages incubated with 10 ,ug native LDL separated from pooled LDL of control subjects by affinity chromatography on mAb-13F6 (Fig. 7 A) , with 10 ,ug in vitro MDA-modified LDL obtained by incubation of the 2616 native LDL with malondialdehyde ( Fig. 7 B) , or with 10 ug MDA-modified LDL isolated from pooled LDL of patients by affinity chromatography on mAbIHI 1 (Fig. 7 C) gina pectoris. After separation of plasma proteins by gel filtration, > 75% of the immunoreactive material applied to the column was recovered in the LDL fraction, whereas no immunoreactivity comigrated with albumin (Fig. 4) . Agarose gel electrophoresis revealed an LDL fraction with increased electrophoretic mobility in the LDL of patients with acute myocardial infarction, but not in the LDL of control subjects (Fig. 5) , which could be isolated with a yield of 74% by ion-exchange chromatography on a mono Q-Sepharose column (Fig. 6) . This material was similar to in vitro MDA-modified LDL standard preparations as in terms of electrophoretic mobility in agarose gels, number of thiobarbituric acid reactive substances, and the affinity for mAb-lHI1.
The titer of MDA-modified LDL specific autoimmune antibodies was previously found to correlate with the progression of carotid atherosclerosis (14) . In the present study, this titer was found to be somewhat higher in patients than in control subjects, but the differences were not statistically significant. Furthermore, the levels of specific autoimmune antibodies were very similar in patients with and without elevated levels of MDA-modified LDL. This suggests that the observed differences in MDA-modified LDL levels are not due to differences in levels of autoimmune antibodies or that there are increased levels of immune complexes present in the plasma of patients.
An LDL subfraction has previously been isolated by ionexchange chromatography (25) from plasma of fasting control persons. This more electronegative fraction, in an amount ranging from 5 to 20% of the total LDL, had a low affinity for high affinity LDL receptors of fibroblasts and a low immunoreactivity with monoclonal antibodies that recognize epitopes of apo B-100 close to the LDL receptor recognition domains, but was not taken up more avidly by macrophages. The characteristics of this LDL subfraction were comparable to these of an oxidation-labile subfraction isolated by Shimano et al. (26) . In the present study, the more electronegative LDL was characterized by a higher number of blocked lysines, resulting in uptake by J774 macrophages and foam cell generation (Fig. 7) . The levels of the modified LDL fraction in the plasma of control subjects were -0.1% of total LDL, whereas they increased to 2% of total LDL in patients with unstable carotid atherosclerosis and patients with acute myocardial infarction.
The increased electrophoretic mobility, the increased lysine modification, the increased cholesterol/protein ratio, and the resulting increased uptake by macrophages of the LDL isolated from the plasma of patients are very similar with these of LDL extracted from atherosclerotic lesions (11, 12) . Furthermore, the levels of linoleate and oleate and of lysophosphatidylcholine were unaltered, suggesting that LDL detected in the plasma of patients might represent LDL released from the arterial wall after rupture of atherosclerotic plaques (32, 33) . Indeed mAb-1H1 1 detected immunoreactive material in or around foam cells (both macrophages and smooth muscle cells) and in the necrotic core of human carotid atherosclerotic lesions.
The finding that the protein moiety of the modified LDL is not fragmented, suggests that the modified LDL does not originate from extensive metal ion-induced oxidation of LDL. It may however be generated by malondialdehyde released by oxidation of arachidonic acid present in LDL. Indeed, it has been shown that interaction with malondialdehyde or 4-hydroxynonenal, another product of prostaglandin synthesis, modifies LDL to an extent that it is recognized by scavenger receptors (18, 34, 35) . Ischemic injury, associated with increased production of free radicals during oxidative stress, may result in the activation of not only the cyclooxygenase-dependent pathway of prostaglandin synthesis in endothelial cells (36), but also in increased production of noncyclooxygenase-derived prostaglandin F2-like compounds, F2-isoprostanes (37, 38) that are strong inducers of platelet aggregation. Activated platelets may then produce large amounts of aldehydes, further enhancing the modification of LDL that infiltrated from the plasma into the intima of atherosclerotic lesions.
In conclusion, the current study presents direct evidence for the occurrence in plasma of MDA-modified LDL that may be atherogenic and suggests that increased plasma levels of MDAmodified LDL may constitute a marker for unstable atherosclerotic disease.
